Lymphoid Infiltrates in B Cell Non Hodgkin’s Lymphoma: Comparing Nuclear Characteristics between Lymph Node and Bone Marrow; and Evaluating Diagnostic Features of Bone Marrow Infiltrates in Paraffin Embedded Tissues by Mark H. Deverell, Elizabeth Best, Jonathan R. Salisbury

“…By comparing neoplastic infiltrates in bone marrow with infiltrates in lymph nodes, the validity of grading non Hodgkin’s lymphoma on the basis of bone marrow histology alone was assessed. 82 cases of B cell non Hodgkin’s lymphoma (44 low grade and 38 high grade), known to have both lymph node and bone marrow involvement at the time of presentation, were compared with bone marrow trephines containing reactive lymphoid infiltrates.…”
Get full text

Acute stimulation of PBMCs drives switch from dopamine-induced anti- to proinflammatory phenotype of monocytes only in women by Leonie Fleige, Silvia Capellino

Subjects: Get full text

Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion by Runhui Zheng, Xiaobo Chen, Chunyan Wang, Pengfei Qin, Huo Tan, Xiaodan Luo

“…Double-expressor diffuse large B-cell lymphoma (DLBCL) with 17p deletion is an aggressive and refractory disease. …”
Get full text

Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma by Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael Jain, Timothy J. Voorhees, Adam S. Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera-Ortega, Agrima Mian, Brian Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont, Steven Le Gouill, Riccardo Masetti, Davide Gori, Alessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani

Get full text

Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5p. by Shengjuan Lu, Lin Zeng, Guojun Mo, Danqing Lei, Yuanhong Li, Guodi Ou, Hailian Wu, Jie Sun, Chao Rong, Sha He, Dani Zhong, Qing Ke, Qingmei Zhang, Xiaohong Tan, Hong Cen, Xiaoxun Xie, Chengcheng Liao

“…SNHG17 expression in B-cell lymphoma cells was detected using qPCR. The effects of SNHG17 with/without doxorubicin on the proliferation and apoptosis of DoHH2 and Daudi were detected. …”
Get full text

Unusual symptoms reveal a rare splenic lymphoma: a case report of PS-DLBCL with neck and shoulder pain as the initial presentation by Shifu Hu, Yuanyuan Hao, Xiangyu Liu, Hanbo Liu

Subjects: “…primary splenic diffuse large B-cell lymphoma…”
Get full text

Multiple Myeloma and B Cell Lymphoma. Investigation of IL-6, IL-6 Receptor Antagonist (IL-6RA), and GP130 Antagonist (GP130A) Using Various Parameters in an In Vitro Model by Eva Kovacs

“…This kind of therapy is not recommended for B cell lymphoma, as these cells have no IL-6R.…”
Get full text

Correction: Long non-coding RNA SNHG17 may function as a competitive endogenous RNA in diffuse large B-cell lymphoma progression by sponging miR-34a-5p. by Shengjuan Lu, Lin Zeng, Guojun Mo, Danqing Lei, Yuanhong Li, Guodi Ou, Hailian Wu, Jie Sun, Chao Rong, Sha He, Dani Zhong, Qing Ke, Qingmei Zhang, Xiaohong Tan, Hong Cen, Xiaoxun Xie, Chengcheng Liao

Get full text

Ocular adnexal lymphoma – A single-center observational study of survival outcomes by Karuvel Kannan Saraswathi, Pragya Saini, Radhakrishnan Santhi, Veerappan Muthukkaruppan, Ayyasamy Vanniarajan, Usha Kim

Subjects: “…b-cell lymphoma…”
Get full text

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression by Agapitos Patakas, Bochong Li, Naveen K Mehta, Kristan Meetze, Patrick A Baeuerle, Jennifer S Michaelson, Hannah M Findlay, Timothy B London

“…CLN-978 bound to CD19 on B cells with picomolar affinity, and to CD3ε on T cells with nanomolar affinity. …”
Get full text

A Case of Primary Breast Diffuse Large B-Cell Lymphoma Treated with Chemotherapy Followed by Elective Field Radiation Therapy: A Brief Treatment Pattern Review from a Radiation Oncologist’s Point of View by Kyu Chan Lee, Seung Heon Lee, KiHoon Sung, So Hyun Ahn, Jinho Choi, Seok Ho Lee, Jae Hoon Lee, Junshik Hong, Sang Hui Park

“…Excisional biopsy revealed low grade lymphoma, which was subsequently confirmed with histopathology and diagnosed as diffuse large B-cell lymphoma (DLBCL). A chest computed tomography scan revealed a 3.5 cm sized breast mass with skin thickening and a small sized lymphadenopathy in the ipsilateral axilla. …”
Get full text

Shift work schedules alter immune cell regulation and accelerate cognitive impairment during aging by Karienn A. de Souza, Morgan Jackson, Justin Chen, Jocelin Reyes, Judy Muayad, Emma Tran, William Jackson, M. Karen Newell-Rogers, David J. Earnest

Subjects: Get full text

Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and cruci... by Annalisa Ciabattini, Elena Pettini, Fabio Fiorino, Jacopo Polvere, Simone Lucchesi, Chiara Coppola, Simone Costagli, Gabiria Pastore, Anna Sicuranza, Monica Tozzi, Arianna Lippi, Francesca Panza, Monica Bocchia, Alessandro Bucalossi, Guido Garosi, David Bennett, Sonia Bernazzali, Massimiliano Fabbiani, Francesca Montagnani, Donata Medaglini

Subjects: Get full text

Transcriptomic and functional characterization of megakaryocytic-derived platelet-like particles: impaired aggregation and prominent anti-tumor effects by Kaitlin Garofano, Vera Mariani, Kameron Rashid, Sumanun Suwunnakorn, Alfateh Sidahmed, Anelia Horvath, Sanjay B. Maggirwar, Travis J. O’Brien, Minoli A. Perera, Michael Whalen, Norman H. Lee

Subjects: Get full text

Cost drivers associated with autologous stem-cell transplant (ASCT) in patients with relapsed/refractory diffuse large B-cell lymphoma in a Japanese real-world setting: A structural equation model (SEM) analysis 2012-2022. by Saaya Tsutsué, Shinichi Makita, Hiroya Asou, Shingo Wada, Wen Shi Lee, Dilinuer Ainiwaer, Koki Idehara, Sona-Sanae Aoyagi, Seok-Won Kim, Todd Taylor

“…Diffuse large B-cell lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma, with increasing incidence, in Japan. …”
Get full text

Dynamic roles of tumor-infiltrating B lymphocytes in cancer immunotherapy by Shishengnan Song, Chong Wang, Yangchao Chen, Xiaorong Zhou, Yi Han, Haijian Zhang

Subjects: “…Tumor-infiltrating B cells…”
Get full text

Mycophenolate mofetil: an update on its mechanism of action and effect on lymphoid tissue by Anna Krawczyk, Bernard Kravčenia, Tomasz Maślanka

Subjects: Get full text

Relationship between the switched memory B level and clinical course of coronavirus disease 2019 in patients with common variable immunodeficiency by Filiz Sadi Aykan, Fatih Çölkesen, Eray Yıldız, Mehmet Kılınç, Recep Evcen, Şevket Arslan

Subjects: “…class-switched memory b cells…”
Get full text

Immunoglobulin M response in largemouth bass (Micropterus salmoides) following ranavirus infection by Zhenyu Huang, Naicheng Liu, Mingyang Xue, Chen Xu, Yuding Fan, Yan Meng, Nan Jiang, Yiqun Li, Wenzhi Liu, Yang He, Yong Zhou

Subjects: “…IgM+ B cells…”
Get full text

Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model by Lin Yang, Ting Chen, Qiuling Zhao, Liangliang Dong, Wanfu Zhong, Wenbin Liu, Xiuliang Qiu, Ruyi Huang, Shengqiang Huang, Ruixiang Xie

“…Objective To evaluate the cost-effectiveness of polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) in CD20-positive patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in China.Design A Markov model was constructed to analyse the cost-effectiveness of two strategies in CD20-positive patients with previously untreated DLBCL over a lifetime horizon: (1) pola-R-CHP and (2) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). …”
Get full text